Total Shareholder Return

As Ethereum faces a slow, structural recovery, a new class of AI crypto agents is booming. Are they competitors, or two sides of the same evolutionary coin?

New research reveals Indigenous-led projects are not just a social good, but a critical economic engine for Canada's energy transition and resource economy.

As National Outlet Shopping Day returns, it's more than a sale. It's Simon's blueprint for the future of retail and a key test of consumer spending.

Canada's new 'AI for All' strategy bets billions on sovereign compute and closing its adoption gap. Can this ambitious plan build a uniquely Canadian AI future?

AM Best affirms Victoria Insurance's 'Good' rating despite a shrinking footprint, revealing a high-stakes balancing act between a fortress balance sheet and immense market risks.

As AI tools offer students instant answers, EdTech firm Thea has served a billion questions instead. We investigate its 'Socratic' model and its ambitious bid to rewire learning.

Fairplay's new user verification signals a market-wide shift. As India's stringent new rules take hold, compliance is becoming a key strategic asset.

As The Conference Board honors S&P Global and UL Solutions, it’s clear that investing in people is no longer a soft skill—it's the core of modern strategy.

QuadReal's appointment of Deloitte veteran Trevor Nakka signals a strategic pivot, adding elite financial governance to its $98.5B portfolio to fuel a disciplined global expansion.

Indian two-wheeler giant TVS Motor outpaced global rivals with a 51% annual return, securing the top spot in a prestigious ranking. What's their formula?

A top financial forum is urging a GST hike, corporate tax cuts, and a radical revamp of retirement savings in its bold 2026 federal budget proposal.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A Miami investment firm made a massive 3.86x return in 8 months by betting that power, not chips, was the real constraint on the AI industry's growth.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

The South Korean tobacco giant hits record revenue as its international strategy pays off, while it diversifies into nicotine pouches for future growth.